2026-01-30 ワシントン大学セントルイス校
<関連情報>
- https://source.washu.edu/2026/01/nasal-vaccine-combats-bird-flu-infection-in-rodents/
- https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00655-X
経鼻アデノウイルスベクターワクチンは、抗原経験のない動物と抗原経験のある動物において、高病原性鳥インフルエンザH5N1から保護する An intranasal adenoviral-vectored vaccine protects against highly pathogenic avian influenza H5N1 in naive and antigen-experienced animals
Baoling Ying ∙ Kelly Pyles ∙ Tamarand L. Darling ∙ … ∙ Eva-Maria Strauch ∙ Michael S. Diamond ∙ Adrianus C.M. Boon
Cell Reports Medicine Published:January 30, 2026
DOI:https://doi.org/10.1016/j.xcrm.2025.102582
Graphical abstract
Highlights
- IN-delivered ChAd-Texas vaccine elicits mucosal antibody and T cell responses
- IN-delivered ChAd-Texas vaccine protects against H5N1 in mice and hamsters
- IN delivery of ChAd-Texas vaccine confers greater protection than IM delivery
- ChAd-Texas induces H5N1 immunity in the setting of prior influenza immunity
Summary
The emergence of highly pathogenic avian H5N1 influenza viruses in dairy cows and humans has increased the potential for another pandemic. To address this risk, we developed chimpanzee adenoviral (ChAd)-vectored H5 hemagglutinin-targeted vaccines and tested their immunogenicity and efficacy in rodents. Immunization with ChAd-Texas (clade 2.3.4.4b) vaccine in mice elicits neutralizing antibody responses and confers protection against viral infection and mortality upon challenge with a human H5N1 isolate (A/Michigan/90/2024, clade 2.3.4.4b). Intranasal delivery of the ChAd-Texas vaccine elicits mucosal antibody and T cell responses and confers greater protection than intramuscular immunization. In Syrian hamsters, a single intranasal dose of ChAd-Texas vaccine prevents weight loss and reduces airway infection after H5N1 A/Michigan/90/2024 or A/Texas/37/2024 challenge. Importantly, prior seasonal influenza vaccination does not impair antibody responses or protection after intranasal delivery of the ChAd-Texas vaccine. These results support the development of mucosally administered ChAd-Texas HA vaccines as an effective platform for HPAI H5N1 preparedness.
